PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
30354208-0	2018	Farnesoid X Receptor Activation by Obeticholic Acid Elevates Liver Low-Density Lipoprotein Receptor Expression by mRNA Stabilization and Reduces Plasma Low-Density Lipoprotein Cholesterol in Mice.	obeticholic acid	35-51	low density lipoprotein receptor	Mus musculus	67-99	
30354208-1	2018	Objective- The objective of this study was to determine whether and how activation of farnesoid X receptor (FXR) by obeticholic acid (OCA), a clinical FXR agonist, modulates liver low-density lipoprotein receptor (LDLR) expression under normolipidemic conditions.	obeticholic acid	116-132	low density lipoprotein receptor	Mus musculus	180-212	
30354208-1	2018	Objective- The objective of this study was to determine whether and how activation of farnesoid X receptor (FXR) by obeticholic acid (OCA), a clinical FXR agonist, modulates liver low-density lipoprotein receptor (LDLR) expression under normolipidemic conditions.	obeticholic acid	116-132	low density lipoprotein receptor	Mus musculus	214-218	
30354208-1	2018	Objective- The objective of this study was to determine whether and how activation of farnesoid X receptor (FXR) by obeticholic acid (OCA), a clinical FXR agonist, modulates liver low-density lipoprotein receptor (LDLR) expression under normolipidemic conditions.	obeticholic acid	134-137	low density lipoprotein receptor	Mus musculus	180-212	
30354208-1	2018	Objective- The objective of this study was to determine whether and how activation of farnesoid X receptor (FXR) by obeticholic acid (OCA), a clinical FXR agonist, modulates liver low-density lipoprotein receptor (LDLR) expression under normolipidemic conditions.	obeticholic acid	134-137	low density lipoprotein receptor	Mus musculus	214-218